Idera Pharmaceuticals, Inc. (IDRA): Price and Financial Metrics


Idera Pharmaceuticals, Inc. (IDRA): $0.43

-0.12 (-21.57%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IDRA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IDRA Stock Price Chart Interactive Chart >

Price chart for IDRA

IDRA Price/Volume Stats

Current price $0.43 52-week high $0.79
Prev. close $0.54 52-week low $0.22
Day low $0.42 Volume 371,800
Day high $0.51 Avg. volume 464,030
50-day MA $0.37 Dividend yield N/A
200-day MA $0.44 Market Cap 26.50M

Idera Pharmaceuticals, Inc. (IDRA) Company Bio


Idera Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. The company was founded in 1989 and is based in Cambridge, Massachusetts.


IDRA Latest News Stream


Event/Time News Detail
Loading, please wait...

IDRA Latest Social Stream


Loading social stream, please wait...

View Full IDRA Social Stream

Latest IDRA News From Around the Web

Below are the latest news stories about IDERA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate IDRA as an investment opportunity.

Idera Pharmaceuticals GAAP EPS of -$0.06, revenue of $0.05M

Idera Pharmaceuticals press release (IDRA): Q3 GAAP EPS of -$0.06.Revenue of $0.05M.The Company’s pro forma cash position as of September 30, 2022 was $26.8 million.

Seeking Alpha | November 14, 2022

Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and operational results for the third quarter ended September 30, 2022. “We are pleased to have completed the merger of Idera and Aceragen at the end of the third quarter, better

Wallstreet:Online | November 14, 2022

Idera Pharma Acquires Rare Disease Player, Names New CEO

Idera Pharmaceuticals Inc (NASDAQ: IDRA ) acquired Aceragen Inc , a privately-held biotechnology company focused on rare, orphan pulmonary, and rheumatic diseases. The combined cash of the two companies is expected to provide a runway into Q3 2023 , funding the advancement of Aceragen''s pipeline, including ACG-701 and ACG-801, through important 2023 clinical milestones. The company estimates an annual peak sales potential of $650 million from … Full story available on Benzinga.com

Benzinga | September 29, 2022

Idera Pharmaceuticals Acquires Aceragen

Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024

GlobeNewswire | September 28, 2022

Idera Pharmaceuticals completes acquisition of Aceragen

Idera Pharmaceuticals (IDRA) has completed the acquisition of privately-held biotechnology company Aceragen in a stock-for-stock transaction.

Seeking Alpha | September 28, 2022

Read More 'IDRA' Stories Here

IDRA Price Returns

1-mo -92.77%
3-mo -94.38%
6-mo -93.89%
1-year -95.70%
3-year -98.48%
5-year -99.83%
YTD -92.77%
2022 -38.60%
2021 -84.47%
2020 101.65%
2019 -34.30%
2018 -83.59%

Continue Researching IDRA

Want to see what other sources are saying about Idera Pharmaceuticals Inc's financials and stock price? Try the links below:

Idera Pharmaceuticals Inc (IDRA) Stock Price | Nasdaq
Idera Pharmaceuticals Inc (IDRA) Stock Quote, History and News - Yahoo Finance
Idera Pharmaceuticals Inc (IDRA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7267 seconds.